Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Debt: 2015-2022

Historic Non-Current Debt for Cartesian Therapeutics (RNAC) over the last 6 years, with Dec 2022 value amounting to $17.8 million.

  • Cartesian Therapeutics' Non-Current Debt fell 39.09% to $13.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $13.8 million, marking a year-over-year decrease of 39.09%. This contributed to the annual value of $17.8 million for FY2022, which is 9.59% down from last year.
  • Cartesian Therapeutics' Non-Current Debt amounted to $17.8 million in FY2022, which was down 9.59% from $19.7 million recorded in FY2021.
  • In the past 5 years, Cartesian Therapeutics' Non-Current Debt registered a high of $24.8 million during FY2020, and its lowest value of $17.8 million during FY2022.
  • Its 3-year average for Non-Current Debt is $20.8 million, with a median of $19.7 million in 2021.
  • Data for Cartesian Therapeutics' Non-Current Debt shows a maximum YoY decreased of 20.65% (in 2021) over the last 5 years.
  • Yearly analysis of 3 years shows Cartesian Therapeutics' Non-Current Debt stood at $24.8 million in 2020, then fell by 20.65% to $19.7 million in 2021, then dropped by 9.59% to $17.8 million in 2022.